











## **Prior Authorization Request Administrative Information**

Member Information							
Last name	First name		МІ				
Member ID	Date of birth						
	X" or Intersex						
Current gender  Female  Male  Transge	Current gender   Female   Male   Transgender male   Transgender female   Other						
Place of residence							
Race/ethnicity Preferred spoken la	anguage	Preferred written lang	uage				
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).							
Plan Contact Information							
Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.							
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan							
☐ MassHealth Drug Utilization Review Prog	gram						
Pharmacy: Fax: (877) 208-7428 - Tel: (800	Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318						
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)							
☐ Fallon Health							
Online Prior Authorization: go.covermymeds.com/OptumRx							
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum							
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033							
☐ Health New England							
Online Prior Authorization: go.covermymeds.com/OptumRx							
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545							
☐ Mass General Brigham Health Plan							
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx							
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org							
Pharmacy: Fax: (844) 403-1029 - Tel: (800)	711-4555						
☐ Tufts Health Plan							
Online Prior Authorization: point32health.promptpa.com							
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985							
☐ WellSense Health Plan							
Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations							
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822							

## **Cystic Fibrosis Agents Prior Authorization Request**

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

Medication information						
Medication requested (Where applicable, the brand na	ime is provided in brackets for reference.)					
☐ Bronchitol (mannitol inhalation powder)	☐ Tobi Podhaler (tobramycin inhalation powder)					
☐ Kalydeco (ivacaftor)	☐ tobramycin inhalation solution [Bethkis]					
☐ Orkambi (lumacaftor/ivacaftor)	☐ Trikafta (elexacaftor/tezacaftor/ivacaftor)					
Symdeko (tezacaftor/ivacaftor)						
Dose, frequency, and duration of medication reques	ted					
Is the member stabilized on the requested medication	on?   Yes. Please provide start date.					
Indication (Check all that apply or include ICD-10 code	, if applicable.)					
Cystic Fibrosis [Please specify genetic mutation(s) be	elow.]					
Does the member have <i>Pseudomonas aeruginosa</i> ?	☐ Yes ☐ No					
☐ Other						
Is this member a referral candidate for care coordination	n? ☐ Yes ☐ No					
If yes, MassHealth will offer care coordination services t						
behavioral health services would be beneficial.						
'						
Section I. Please complete for initial requests f	for Kalydeco, Orkambi, Symdeko, and Trikafta.					
1. Please document member's baseline body mass inde	ex (BMI).					
2. For members > 6 years of age, please document mer	` ,					
volume in one second (ppFEV1).	Date					
Section II. Please complete for recertification re	equests for Kalydeco, Orkambi, Symdeko, and					
Trikafta.	<u> </u>					
Please document member's current BMI.	Date					
Has the member demonstrated an improvement in E						
2. For members > 6 years of age, please document me						
ge, preside desamonente						
	Date					
Has the member demonstrated an improvement in lu	ING TUNCTION (     YES     INO					

PA-68 (Rev.04/24) over

3.	Has the member demonstrated a reduced frequency of clinical exacerbations since initiating the requested medication?   Yes  No				
	If yes, please describe.				
4.	If member has not demonstrated improvement in the ppFEV1, BMI or frequency of clinical exacerbations, please document response to therapy.				
200	otion III — Diagon complete for Tabi Dadbalar and tabramyain inhalation calution (generic				
sec	ction III. Please complete for Tobi Podhaler and tobramycin inhalation solution (generic Bethkis) requests.				
	Has the member had a trial with tobramycin inhalation solution?				
	Yes. Please list the dose and frequency, dates/duration of trials, and outcomes below.				
	Dose and frequency Dates/duration of use				
	Did the member experience any of the following?  Adverse reaction Inadequate response Other Briefly describe details of adverse reaction, inadequate response, or other.				
	Briefly describe details of daverse reaction, madequate response, or other.				
	☐ No. Please explain.				
1.	ction IV. Please complete for Bronchitol requests.  Documentation that member has passed the Bronchitol Tolerance Test  Yes  No  Has the member had a trial with Pulmozyme?				
	Yes. Please list the dose and frequency, dates/duration of trials, and outcomes below.				
	Dose and frequency Dates/duration of use				
	Did the member experience any of the following?  Adverse reaction  Inadequate response  Other Briefly describe details of adverse reaction, inadequate response, or other.				
3.	Has the member had a trial with sodium chloride for inhalation?  — Yes. Please list the dose and frequency, dates/duration of trials, and outcomes below.				
	Dose and frequency Dates/duration of use				
	Did the member experience any of the following?   Adverse reaction   Inadequate response   Other Briefly describe details of adverse reaction, inadequate response, or other.				
Sec	ction V. Please include any other pertinent information (if needed).				
Γ					
2-	etian VI. Diagon complete and manide decompartation for accombinate to Otan Thomas				
	ction VI. Please complete and provide documentation for exceptions to Step Therapy.  Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse				
	reaction in, or physical or mental harm to the member?   Yes No				

	If yes, briefly describe details of contraindication, adverse reaction, or harm.					
2.	Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?  Yes No					
	If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.					
3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?  ☐ Yes ☐ No					
	If yes, please provide details for the previous trial.  Drug name  Dates/duration of use  Did the member experience any of the following?   Adverse reaction   Inadequate response  Briefly describe details of adverse reaction or inadequate response.					
4.	Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?  Yes. Please provide details.					

Please continue to next page and complete Prescriber and Provider Information section.

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification?  Yes	] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider  (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)